References
1. Celli BR, Wedzicha JA. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. The New England journal of medicine 2019; 381 : 1257-66.
2. Collaborators GBDCRD. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Respiratory medicine 2020; 8 : 585-96.
3. Wang C, Xu J, Yang L et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet 2018; 391 : 1706-17.
4. Chan KY, Li X, Chen W et al. Prevalence of chronic obstructive pulmonary disease (COPD) in China in 1990 and 2010. Journal of global health 2017; 7 : 020704.
5. Zhu B, Wang Y, Ming J et al. Disease burden of COPD in China: a systematic review. Int J Chron Obstruct Pulmon Dis 2018; 13 : 1353-64.
6. Lou P, Zhu Y, Chen P et al. Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: a cross-sectional case control study. BMC pulmonary medicine 2012;12 : 53.
7. GOLD-Workshop. 2020 GOLD Reports. 2020 Global Strategy for Prevention, Diagnosis and Management of COPD. https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. 2020.
8. May SM, Li JT. Burden of chronic obstructive pulmonary disease: healthcare costs and beyond.Allergy and asthma proceedings 2015; 36 : 4-10.
9. Zhou Y, Bruijnzeel PL, McCrae C et al. Study on risk factors and phenotypes of acute exacerbations of chronic obstructive pulmonary disease in Guangzhou, China-design and baseline characteristics. Journal of thoracic disease 2015;7 : 720-33.
10. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 2001; 164 : 580-4.
11. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003;124 : 459-67.
12. Escarrabill J. Discharge planning and home care for end-stage COPD patients. The European respiratory journal 2009; 34 : 507-12.
13. Fermont JM, Bolton CE, Fisk M et al. Risk assessment for hospital admission in patients with COPD; a multi-centre UK prospective observational study. PloS one 2020;15 : e0228940.
14. Fuschillo S, Molino A, Stellato C et al. Blood eosinophils as biomarkers of therapeutic response to chronic obstructive pulmonary disease: Still work in progress.European journal of internal medicine 2019; 68 : 1-5.
15. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2006; 1 : 39-47.
16. Wu HX, Zhuo KQ, Cheng DY. Prevalence and Baseline Clinical Characteristics of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-Analysis and Systematic Review.Frontiers in medicine 2019; 6 : 282.
17. Bafadhel M, Greening NJ, Harvey-Dunstan TC et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD Chest 2016; 150 : 320-8. DOI: 10.1016/j.chest.2016.01.026. .
18. Bafadhel M, Peterson S, De Blas MA et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. The Lancet Respiratory medicine 2018;6 : 117-26.
19. Zhang Y, Liang LR, Zhang S et al. Blood Eosinophilia and Its Stability in Hospitalized COPD Exacerbations are Associated with Lower Risk of All-Cause Mortality. Int J Chron Obstruct Pulmon Dis 2020; 15 : 1123-34.
20. Prins HJ, Duijkers R, Lutter R et al. Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD. Respiratory medicine 2017;131 : 118-24.
21. Couillard S, Larivee P, Courteau J, Vanasse A. Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions. Chest 2017; 151 : 366-73.
22. Singh D, Kolsum U, Brightling CE et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. The European respiratory journal 2014;44 : 1697-700. DOI:10.183/09031936.0162414.
23. Cai BQ, Cai SX, Chen RC et al. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People’s Republic of China. Int J Chron Obstruct Pulmon Dis 2014; 9 : 381-95.
24. Chinese Chronic Obstructive Pulmonary Diseases Study Group Chinese Society of Respiratory Diseases. Guideline for diagnosis and management of chronic obstructive pulmonary diseases in China (Revised 2013). . Chin J Tubere Respir Dis2013; 36 : 255-64.
25. Chinese Thoracic Society. The guideline of community-acquired pneumonia diagnosis and treatment.Chin J Tuberc Resp Dis 2006; 29 : 651-5.
26. Wu HX, Zhuo KQ, Cheng DY. Peripheral Blood Eosinophil as a Biomarker in Outcomes of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2019; 14 : 3003-15.
27. Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. The European respiratory journal 2004; 23 : 932-46.
28. Aydindogan E, Penque D, Zoidakis J. Systematic review on recent potential biomarkers of chronic obstructive pulmonary disease. Expert review of molecular diagnostics 2019; 19 : 37-45.
29. Wu CW, Lan CC, Hsieh PC et al. Role of peripheral eosinophilia in acute exacerbation of chronic obstructive pulmonary disease. World journal of clinical cases2020; 8 : 2727-37.
30. Russell R, Beer S, Pavord ID et al. The acute wheezy adult with airways disease in the emergency department: a retrospective case-note review of exacerbations of COPD.Int J Chron Obstruct Pulmon Dis 2019; 14 : 971-7.
31. Eltboli O, Bafadhel M, Hollins F et al. COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC pulmonary medicine 2014; 14 : 112.
32. Coyle AJ, Wagner K, Bertrand C et al. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. The Journal of experimental medicine 1996; 183 : 1303-10.
33. Wei B, Sheng Li C. Changes in Th1/Th2-producing cytokines during acute exacerbation chronic obstructive pulmonary disease. The Journal of international medical research 2018; 46 : 3890-902.
34. Bafadhel M, McKenna S, Terry S et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. American journal of respiratory and critical care medicine 2012; 186 : 48-55. DOI:10.1164/rccm.201108-1553OC.
35. Ritchie AI, Wedzicha JA. Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations. Clinics in chest medicine 2020; 41 : 421-38.
36. Serafino-Agrusa L, Scichilone N, Spatafora M, Battaglia S. Blood eosinophils and treatment response in hospitalized exacerbations of chronic obstructive pulmonary disease: A case-control study. Pulmonary pharmacology & therapeutics 2016;37 : 89-94. DOI: 10.1016/j.pupt.2016.03.004.
37. Mollica M, ;, Aronne L, Paoli G et al. Elderly with COPD: comoborbitidies and systemic consequences (online first). Journal of Gerontology and Geriatrics 2020.